

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

May 26, 2021

Monica Brady Chief Financial Officer ProPhase Labs, Inc. 711 Stewart Ave, Suite 200 Garden City, NY 11530

Re: ProPhase Labs, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2020
File No. 000-21617
Filed March 31, 2021

Dear Ms. Brady:

We have limited our review of your filing to the financial statements and related disclosures and have the following comment. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response.

After reviewing your response to this comment, we may have additional comments.

Form 10-K for the Fiscal Year Ended December 31, 2020

<u>Item 8. Financial Statements and Supplementary Data</u> <u>Note 3 - Business Acquisition, page 46</u>

1. You disclose that on October 23, 2020, you acquired all of the issued and outstanding shares of capital stock of Confucius Plaza Medical Laboratory Corp. for approximately \$2.5 million in cash. Tell us how you considered Rules 3-05 and 8-04 of Regulation S-X in evaluating the significance of the acquisition of Confucius Plaza Medical Laboratory Corp. and whether you are required to include audited financial statements and pro forma information under Article 11 of Regulation S-X.

In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Monica Brady ProPhase Labs, Inc. May 26, 2021 Page 2

You may contact Lynn Dicker at (202) 551-3616 or Kevin Kuhar, Accounting Branch Chief at (202) 551-3662 with any questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences